Sarepta Therapeutics Inc. (SRPT) Financials Nov 20
Post# of 250602
Posted On: 11/20/2014 10:01:27 PM
Sarepta Therapeutics Inc. (SRPT) Financials Nov 20, 2014, 7:57 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Sarepta Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 17.59M 29.42M 46.99M 37.33M 14.22M
Cost of Goods Sold (COGS) incl. D&A - - 1.3M - -
COGS excluding D&A - - 0 - -
Depreciation & Amortization Expense 1.38M 1.46M 1.3M 1.53M 1.28M
Depreciation 1.15M 1.22M 838,000 975,000 800,000
Amortization of Intangibles 225,000 246,000 462,000 550,000 477,000
Gross Income - - 45.69M - -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 31.71M 48.89M 80.47M 65.32M 101.93M
Research & Development 23.02M 35.97M 66.31M 52.33M 71.71M
Other SG&A 8.7M 12.92M 14.16M 12.99M 30.22M
Other Operating Expense 0 0 0 0 0
Unusual Expense 9.2M 11.5M (31.88M) 92.12M 23.33M
EBIT after Unusual Expense (9.2M) (11.5M) 31.88M (92.12M) (23.33M)
Non Operating Income/Expense 0 0 0 135,000 200,000
Non-Operating Interest Income 0 259,000 587,000 219,000 126,000
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 454,000 - - - -
Gross Interest Expense 454,000 - - - -
Interest Capitalized - 0 0 - -
Pretax Income (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
Minority Interest Expense 0 0 0 0 0
Net Income (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
EPS (Basic) (1.62) (1.74) (0.12) (5.14) (3.31)
Basic Shares Outstanding 15.52M 18.54M 21.6M 23.6M 33.85M
EPS (Diluted) (1.62) (1.74) (0.12) (5.14) (3.31)
Diluted Shares Outstanding 15.52M 18.54M 21.6M 23.6M 33.85M
EBITDA (14.13M) (19.47M) (33.48M) (27.99M) (87.71M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Sarepta Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 17.59M 29.42M 46.99M 37.33M 14.22M
Cost of Goods Sold (COGS) incl. D&A - - 1.3M - -
COGS excluding D&A - - 0 - -
Depreciation & Amortization Expense 1.38M 1.46M 1.3M 1.53M 1.28M
Depreciation 1.15M 1.22M 838,000 975,000 800,000
Amortization of Intangibles 225,000 246,000 462,000 550,000 477,000
Gross Income - - 45.69M - -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 31.71M 48.89M 80.47M 65.32M 101.93M
Research & Development 23.02M 35.97M 66.31M 52.33M 71.71M
Other SG&A 8.7M 12.92M 14.16M 12.99M 30.22M
Other Operating Expense 0 0 0 0 0
Unusual Expense 9.2M 11.5M (31.88M) 92.12M 23.33M
EBIT after Unusual Expense (9.2M) (11.5M) 31.88M (92.12M) (23.33M)
Non Operating Income/Expense 0 0 0 135,000 200,000
Non-Operating Interest Income 0 259,000 587,000 219,000 126,000
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 454,000 - - - -
Gross Interest Expense 454,000 - - - -
Interest Capitalized - 0 0 - -
Pretax Income (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
Minority Interest Expense 0 0 0 0 0
Net Income (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (25.16M) (32.18M) (2.32M) (121.29M) (111.99M)
EPS (Basic) (1.62) (1.74) (0.12) (5.14) (3.31)
Basic Shares Outstanding 15.52M 18.54M 21.6M 23.6M 33.85M
EPS (Diluted) (1.62) (1.74) (0.12) (5.14) (3.31)
Diluted Shares Outstanding 15.52M 18.54M 21.6M 23.6M 33.85M
EBITDA (14.13M) (19.47M) (33.48M) (27.99M) (87.71M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)Scroll down for more posts ▼